Market Overview

Arcus Biosciences Announces Participation at Two Investor Conferences in September

Share:

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced the Company will be participating in the following upcoming
investor conferences:

  • Citi's 13th Annual Biotech Conference in Boston on Wednesday,
    September 5, 2018. At 3:15 pm ET, Terry Rosen, Ph.D., Chief Executive
    Officer, will participate in a panel discussion entitled, "Targeted
    Therapies Oncology – Aiming for the Bull's Eye."
  • Morgan Stanley 16th Annual Global Healthcare Conference in New York
    City on Thursday, September 13, 2018. At 4:40 pm ET, Terry Rosen,
    Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating
    Officer and Chief Financial Officer, will participate in a fireside
    chat. Individuals may access the live audio webcast of the fireside
    chat by visiting the "Events & Presentations" section of the Company's
    website at https://investors.arcusbio.com/investors/events-and-presentations.
    A replay of the webcast will be available for 30 days following the
    live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus's other product
candidates. Arcus's other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in IND-enabling studies. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry, pharmacology
and structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.

View Comments and Join the Discussion!